A new study conducted at Tel Aviv University and Sheba Medical Center reveals how melanoma cancer cells affect their close environment to support their needs by forming new lymph vessels in the dermis, to go deeper into the skin and spread through the body. The researchers believe the discovery may contribute to the development of a vaccine against the deadly cancer.
The scientific breakthrough was led by Prof. Carmit Levy of TAU’s Faculty of Medicine and Prof. Shoshana Greenberger from the Sheba Medical Center. The study was funded by ICRF (the Israel Cancer Research Fund) and its results appeared in the Journal of Investigative Dermatology published by Nature (Primary melanoma miRNAs trafficking induce lymphangiogenesis).
Melanoma, the deadliest of all skin tumors, starts with the uncontrolled division of melanocyte cells in the epidermis – the top layer of the skin. In the second stage, the cancer cells penetrate the dermis and metastasize through the lymphatic and blood systems. In previous studies a dramatic rise was observed in the density of lymph vessels in the skin around the melanoma – a mechanism that was not understood by researchers until now.
“Our main research question was how melanoma impacts the formation of lymph vessels, through which it then metastasizes,” explains Prof. Greenberger. “We demonstrated for the first time that in the first stage, in the epidermis, melanoma cells secrete extracellular vesicula called melanosomes.”
“What are these vesicula and how do they impact their environment? Examining this in human melanomas from the Pathology Institute, we demonstrated that melanosomes can penetrate lymph vessels. Then we examined their behavior in the environment of actual lymph vessel cells and found that here too the melanosomes penetrate the cells and give them a signal to replicate and migrate. In other words, the primary melanoma secretes extracellular vesicula that penetrate lymph vessels and encourage the formation of more lymph vessels near the tumor, enabling the melanoma to advance to the lethal stage of metastasis,” Prof. Greenberger says.
Prof. Carmit Levy adds: “Melanoma cells secrete the extracellular vesicula, termed “melanosomes,” before cancer cells reach the dermis layer of the skin. These vesicles modify the dermis environment to favor cancer cells. Therefore, melanoma cells are responsible for enriching the dermis with lymph vessels, thereby preparing the substrate for their own metastasis. We have several continuing studies underway, demonstrating that the melanosomes don’t stop at the lymph cells, as they also impact the immune system, for example.”
Since melanoma is not dangerous at the premetastatic stage, understanding the mechanism by which the metastases spread via the lymphatic and blood systems can hopefully contribute to the development of a vaccine against this deadly cancer.
“Melanoma that remains on the skin is not dangerous,” says Prof. Greenberger. “Therefore, the most promising direction for fighting melanoma is immunotherapy: developing a vaccine that will arouse the immune system to combat the melanosomes, and specifically to attack the lymphatic endothelial cells already invaded by the melanosomes. If we can stop the mechanisms that generate metastases in lymph nodes, we can also stop the disease from spreading.”
